Physician profile
Joseph Morelos
NPI 1861498693
$30,064.47
in general payments reported to CMS, 2019-2025
57 companies · $4,283 in 2025
The $4,283 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,169 · 2020: $3,150 · 2021: $3,984 · 2022: $6,552 · 2023: $4,058 · 2024: $4,869 · 2025: $4,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,210.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,240.08 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Abbvie INC. | $5,074.77 | 2021-2025 | |
| Novo Nordisk INC | $2,364.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,705.88 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,610.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,111.85 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $887.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $877.74 | 2019-2025 | Jardiance |
| Pfizer INC. | $875.94 | 2019-2025 | |
| Amgen INC. | $728.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $714.27 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $652.18 | 2019-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $476.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $418.20 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $402.45 | 2021-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Morelos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.